FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET. A live webcast of the fireside chat will be av ...

Group 1 - Terns Pharmaceuticals, Inc. (TERN) has experienced a significant downtrend, with a stock decline of 39.8% over the past four weeks, indicating excessive selling pressure [1] - The stock is currently in oversold territory, as evidenced by an RSI reading of 21.87, suggesting a potential reversal in trend [5] - Wall Street analysts have shown strong agreement in raising earnings estimates for TERN, with a 6.5% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7] Group 2 - TERN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

A downtrend has been apparent in Terns Pharmaceuticals, Inc. (TERN) lately with too much selling pressure. The stock has declined 31.4% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical ...

FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Comp ...

Terns Pharmaceuticals, Inc. (TERN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39926 Terns Pharmaceuticals, Inc. (Exact name of Registrant as specified in its Charter) Delaware 98-1448275 (State or other jurisdic ...

[Report Overview and Key Highlights](index=1&type=section&id=Terns%20Pharmaceuticals%20Reports%20Fourth%20Quarter%20and%20Full%20Year%202024%20Financial%20Results%20and%20Corporate%20Updates) - Announced significant clinical progress in **2024** for its lead programs, TERN-701 in CML and TERN-601 in obesity, with key data readouts expected in **2025**[2](index=2&type=chunk) - The dose expansion for the Phase 1 CARDINAL trial of TERN-701 (CML) is expected to start in **Q2 2025**, with additional data anticipated in **Q4 2025**[1](index=1&type=chunk) - The first patient was enrolled in the Phase 2 FALCON trial of TERN-601 (obesity), with **12-week** data expected in **Q4 2025**[1](index=1&type=chunk) - The company reports a strong financial position with **$358 million** in cash, cash equivalents, and marketable securities, providing an expected operational runway into **2028**[1](index=1&type=chunk) [Pipeline Developments and Anticipated Milestones](index=1&type=section&id=Recent%20Pipeline%20Developments%20and%20Anticipated%20Milestones) [TERN-701 for Chronic Myeloid Leukemia (CML)](index=1&type=section&id=TERN-701%3A%20Oral%2C%20allosteric%20BCR-ABL%20tyrosine%20kinase%20inhibitor%20%28TKI%29%20for%20chronic%20myeloid%20leukemia%20%28CML%29) TERN-701, an oral TKI for CML, completed Phase 1 dose escalation with compelling molecular responses and favorable safety, with dose expansion starting Q2 2025 and data expected Q4 2025 - Phase 1 dose escalation was completed in **January 2025**, with interim data showing compelling molecular responses and an encouraging safety profile in heavily pre-treated CML patients[3](index=3&type=chunk) - Positive drug-drug interaction (DDI) data indicates TERN-701 is not a clinically relevant inhibitor of CYP3A4 or OATP1B1/3, representing a key safety differentiation within its class[3](index=3&type=chunk) - The dose expansion part of the Phase 1 study is expected to start in **Q2 2025**, with additional safety and efficacy data anticipated in **Q4 2025**[3](index=3&type=chunk) [TERN-601 for Obesity](index=2&type=section&id=TERN-601%3A%20Oral%2C%20small-molecule%20glucagon-like%20peptide-1%20%28GLP-1%29%20receptor%20agonist%20for%20obesity) TERN-601, an oral GLP-1 agonist for obesity, enrolled its first Phase 2 FALCON patient; 12-week data expected Q4 2025, evaluating efficacy and safety with a slower titration schedule - The Phase 2 FALCON clinical trial enrolled its first patient in **March 2025**, with **12-week** data expected in **Q4 2025**[6](index=6&type=chunk) - The trial's primary endpoint is the percent change from baseline in body weight compared to placebo over **12 weeks**[6](index=6&type=chunk) - The Phase 2 trial will use a slower titration schedule (**two to four weeks** at each intermediate dose) to aim for competitive weight loss with best-in-class tolerability[6](index=6&type=chunk) [Other Pipeline Programs (TERN-501 & TERN-800 Series)](index=2&type=section&id=TERN-501%20and%20TERN-800%20Series) Terns evaluates TERN-501 for metabolic diseases, potentially with GLP-1s, and advances TERN-800 series GIPR modulators, prioritizing a GIPR antagonist for obesity combination therapies - TERN-501 (THR-β agonist): The company continues to evaluate opportunities for TERN-501 in metabolic diseases, noting its complementary mechanism to GLP-1 for potential broader benefits[6](index=6&type=chunk) - TERN-800 Series (GIPR modulators): Discovery efforts are ongoing, with a focus on nominating a GIPR antagonist candidate to combine with GLP-1 agonists like TERN-601 for obesity treatment[6](index=6&type=chunk) [Corporate Updates](index=3&type=section&id=Corporate%20Updates) Terns strengthened its leadership by appointing Andrew Gengos as CFO and adding Robert Azelby and Heather Turner to its board of directors - In **February 2025**, Andrew Gengos was appointed as Chief Financial Officer[11](index=11&type=chunk) - In **February 2025**, Robert Azelby was appointed to the board of directors[11](index=11&type=chunk) - In **November 2024**, Heather Turner was appointed to the board of directors[11](index=11&type=chunk) [Fourth Quarter and Full Year 2024 Financial Results](index=3&type=section&id=Fourth%20Quarter%20and%20Full%20Year%202024%20Financial%20Results) [Financial Summary](index=3&type=section&id=Financial%20Summary) Terns ended 2024 with $358.2 million cash, providing runway into 2028; R&D increased, G&A decreased, and net loss narrowed to $88.9 million - Cash, cash equivalents, and marketable securities were **$358.2 million** as of **Dec 31, 2024**, compared to **$263.4 million** a year prior. The company expects these funds to be sufficient to support operations into **2028**[8](index=8&type=chunk) Comparison of Key Financial Metrics (Full Year) | Metric | FY 2024 (Millions USD) | FY 2023 (Millions USD) | Change | | :--- | :--- | :--- | :--- | | R&D Expenses | $70.1 | $63.5 | +10.4% | | G&A Expenses | $31.8 | $39.1 | -18.7% | | Net Loss | $88.9 | $90.2 | -1.4% | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported a net loss of $21.8 million for Q4 2024 and $88.9 million for FY 2024, with full-year net loss per share improving to $(1.12) from $(1.27) in 2023 Statement of Operations Highlights (in thousands, except per share data) | Metric | Q4 2024 (Thousands USD) | Q4 2023 (Thousands USD) | FY 2024 (Thousands USD) | FY 2023 (Thousands USD) | | :--- | :--- | :--- | :--- | :--- | | R&D Expenses | $18,004 | $17,459 | $70,112 | $63,497 | | G&A Expenses | $7,945 | $6,599 | $31,759 | $39,061 | | Total Operating Expenses | $25,949 | $24,058 | $101,871 | $102,558 | | Net Loss | $(21,799) | $(21,019) | $(88,853) | $(90,210) | | Net Loss Per Share | $(0.24) | $(0.29) | $(1.12) | $(1.27) | [Selected Balance Sheet Data](index=4&type=section&id=Selected%20Balance%20Sheet%20Data) As of December 31, 2024, Terns' cash, cash equivalents, and marketable securities significantly increased to $358.2 million from $263.4 million, with total assets growing to $363.9 million and stockholders' equity to $345.9 million Balance Sheet Highlights (in thousands) | Metric | Dec 31, 2024 (Thousands USD) | Dec 31, 2023 (Thousands USD) | | :--- | :--- | :--- | | Cash, cash equivalents and marketable securities | $358,164 | $263,440 | | Total assets | $363,929 | $268,517 | | Total liabilities | $18,059 | $13,150 | | Total stockholders' equity | $345,870 | $255,367 |

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 Cash, cash equivalents and marketable securities of $358 million, expected to provide runway into 2028 FOSTER CITY, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-st ...

Core Viewpoint - Terns Pharmaceuticals is positioned as a small-cap biotech with significant upside potential in the weight loss therapeutic area, particularly with its investigational drugs TERN-601 and TERN-501, which are nearing phase 2 studies [1][2]. Group 1: Company Overview - Terns Pharmaceuticals focuses on developing weight loss and oncology medicines, with TERN-601 and TERN-501 as its leading candidates in the anti-obesity field [2][3]. - The average price target for Terns Pharmaceuticals' stock is $19.06, suggesting a potential increase of approximately 462% from current levels [2]. Group 2: Product Pipeline - TERN-601 is a potential once-daily oral GLP-1 medicine, which could appeal to patients preferring oral formulations over injected alternatives. In a phase 1 study, it achieved a statistically significant mean weight loss of 5.5% [2]. - TERN-501 aims to enhance the efficacy of GLP-1 medicines by stabilizing energy expenditures during weight loss, which could lead to its standard use alongside GLP-1 therapies if proven effective [3]. Group 3: Clinical Development - Terns Pharmaceuticals is also developing TERN-701, a potential cancer treatment that has shown positive interim data in a phase 1 study for chronic myeloid leukemia, with more data expected in the fourth quarter [4]. - Both TERN-601 and TERN-501 have not yet entered phase 2 studies, and their mid-stage data could serve as major catalysts for the stock price [5]. Group 4: Market Competition and Challenges - The competitive landscape for oral GLP-1 medicines is intensifying, with other companies advancing ahead of Terns Pharmaceuticals in this area [7][8]. - Terns previously abandoned the development of TERN-501 for metabolic dysfunction-associated steatohepatitis (MASH) after phase 2 trials, highlighting the challenges in developing successful therapies in crowded fields [6][7].

Core Points - Terns Pharmaceuticals, Inc. has granted an equity inducement award to Andrew Gengos, the new chief financial officer, as a material inducement for his acceptance of employment [1] - The equity award consists of an option to purchase 750,000 shares of Terns common stock at an exercise price of $3.73, which is the closing price on February 24, 2025 [2] - The option has a 10-year term and vests over four years, contingent on Mr. Gengos' continued service [2] Company Overview - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates targeting serious diseases such as oncology and obesity [3] - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort [3]